Therapeutic Angiogenesis for Cardiovascular Disease by Ng, Yin-Shan & D'Amore, Patricia A.
 
Therapeutic Angiogenesis for Cardiovascular Disease
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ng, Yin-Shan, and Patricia A D'Amore. 2001. Therapeutic
angiogenesis for cardiovascular disease. Current Controlled Trials
in Cardiovascular Medicine 2(6): 278-285.
Published Version doi:10.1186/cvm-2-6-278
Accessed February 19, 2015 7:44:54 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4931127
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAang = angiopoietin; CEP = circulating endothelial precursor; FGF = fibroblast growth factor; FGF-1 = acidic fibroblast growth factor; FGF-2 =
basic fibroblast growth factor; HIF-1α = hypoxia inducible factor-1 alpha; SPECT = single photon emission computed tomography; VEGF = vascu-
lar endothelial growth factor.
Current Controlled Trials in Cardiovascular Medicine    December 2001 Vol 2 No 6 Ng and D’Amore
Angiogenesis is the growth of blood vessels from a pre-exist-
ing vessel bed. Clinical interest in the control of angiogenesis
arises from two distinct quarters. In one case, the goal is to
block the growth of new vessels as a means to suppress
and/or regress tumor growth, or to suppress vessel prolifera-
tion in pathologies such as diabetes. In the second case, the
objective is to induce or stimulate vessel growth in patients
with conditions characterized by insufficient blood flow, such
as ischemic heart disease and peripheral vascular diseases.
The latter applications are the focus of this review. We
discuss some of the recent efforts to induce new vessel
growth and we highlight challenges that have arisen regarding
the means of delivery and efficacy of angiogenesis induction.
Angiogenic stimuli
Both basic fibroblast growth factor (FGF-2) and vascular
endothelial growth factor (VEGF)-A have been used in
attempts to stimulate angiogenesis.
Fibroblast growth factor
The fibroblast growth factor (FGF) family consists of an ever-
increasing number of peptide growth factors with diverse cel-
lular targets and biological effects [1]. Two family members,
acidic fibroblast growth factor (FGF-1) and FGF-2, have a
strong affinity for heparin and have been studied for their
effects on vascular cells, including endothelial cells and
smooth muscle cells. Extensive evidence indicates that both
FGF-1 and FGF-2 are potent angiogenic factors, providing
support for their use as stimuli for therapeutic angiogenesis in
vivo. It is also important to note that many cell types express
one of the four FGF receptors, and that FGF has been shown
to have biological effects in a number of cell systems includ-
ing induction of neurite outgrowth, suppression of skeletal
muscle differentiation, induction of bone formation and neuro-
protection, to name just a few.
Vascular endothelial growth factor-A
VEGF-A is the prototypic member of a family of secreted,
homodimeric glycoproteins with endothelial cell-specific mito-
genic activity and the ability to stimulate angiogenesis in vivo
[2]. VEGF-A also increases vascular permeability, with an
effect 10,000 times more potent than that of the vasoactive
substance histamine; VEGF-A was originally purified based
on this property, and was named vascular permeability factor
[3]. The VEGF-A family of polypeptides consists of a number
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Abstract
The identification of angiogenic growth factors, such as vascular endothelial growth factor and
fibroblast growth factor, has fueled interest in using such factors to induce therapeutic angiogenesis.
The results of numerous animal studies and clinical trials have offered promise for new treatment
strategies for various ischemic diseases. Increased understanding of the cellular and molecular biology
of vessel growth has, however, prompted investigators and clinicians alike to reconsider the complexity
of therapeutic angiogenesis. The realization that formation of a stable vessel is a complex, multistep
process may provide useful insights into the design of the next generation of angiogenesis therapy.
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of biochemically distinct isoforms (three isoforms in the
mouse and up to five in humans) that are generated through
alternative mRNA splicing of a single gene [4,5]. The iso-
forms are named by the number of amino acids that comprise
the proteins; the human isoforms include VEGF121,
VEGF145, VEGF165, VEGF189, and VEGF206.
Preclinical studies
Current clinical trials of angiogenesis factors were preceded
by a large number of studies using animal models of cardiac
or peripheral ischemia. Early studies involved protein adminis-
tration, whereas later efforts began to employ gene therapy.
In one early study using recombinant protein, a single intra-
arterial injection of 500–1000 µg VEGF165 into rabbits with
severe experimental hind limb ischemia increased collateral
vessels, as detected by angiography and histological analysis
[6]. Naked plasmid DNA injected directly into the skeletal
muscle in a later study, using the same hind limb ischemia
model, also yielded increased collateral vessels, as deter-
mined by angiography and improved perfusion [7].
Although such reports of increased vessel growth and func-
tional improvement in response to exogenously administered
angiogenic factors are encouraging, it is essential to note that
animal models such as the ischemic hind limb model have def-
inite limitations. Whereas the ischemia in the animal models is
acute (produced by surgical procedure), the ischemia that
characterizes the human disease often arises over an
extended time and occurs in the context of complex athero-
sclerotic processes. The responses seen in the experimental
models may thus be quite different in terms of the kinetics of
vessel growth as well as the nature of the resultant vessels.
In a study assessing the effects of VEGF-A on myocardial
ischemia in a porcine model of progressive coronary artery
occlusion, VEGF-A was delivered by osmotic pump and mag-
netic resonance mapping revealed a reduction in the size of
the ischemic zone and improved cardiac function [8]. A single
bolus injection was also found to produce significant
improvements in myocardial blood flow and function [9].
Myocardial ischemia in animals has also been treated with
FGF. Delivery of FGF-2 via implantation of heparin-alginate
beads led to an 80% reduction in infarct size and improved
cardiac function in pigs with experimentally induced coronary
artery constrictions, as compared with untreated controls
[10]. These studies were followed closely by the demonstra-
tion of gene therapy in a porcine model of stress-induced
myocardial ischemia. Intracoronary injection of a recombinant
adenovirus expressing another member of the FGF family,
human FGF-5, led to improvements in stress-induced func-
tion and blood flow that were maintained for 12 weeks [11].
Clinical trials
Results from basic research have proven that both VEGF-A
and FGF-2 are potent angiogenic factors, and the use of
these factors in animal models has indicated that they have
therapeutic potential. The two factors have therefore been
entered into clinical trials, testing their ability to provide angio-
genesis therapy for various diseases in which new vessel
growth is desirable. Both VEGF-A and FGF-2 have been
tested in phase I clinical trials, with mixed results [12,13].
Although phase I trials are not designed to test efficacy, many
important insights regarding the potential obstacles to using
angiogenic therapies have become evident.
Fibroblast growth factor
In one study, human recombinant FGF-2 was administered
intraoperatively to areas of the coronary artery in 20 patients
who were undergoing surgical revascularization [14]. Angio-
graphic analysis revealed evidence of collateralization. Local
sustained release of high dose (but not low dose) FGF-2 to
ischemic areas, in 24 patients during bypass surgery, led to a
reduction in stress defect size [15]. In a recent study involving
59 patients with coronary disease, the response to intravenous
or intracoronary human recombinant FGF-2 was monitored by
single photon emission computed tomography (SPECT)
imaging [16]. Perfusion was monitored at approximately 1, 2,
and 3 months after growth factor administration. Analysis of
global stress perfusion or inducible ischemia revealed a consis-
tent and sustained reduction in the extent and severity of
stress-inducible ischemia, as well as an improvement in resting
perfusion in areas where there was a risk of ischemia.
Vascular endothelial growth factor
In an early phase I trial to test the safety and bioactivity of
VEGF-A, naked VEGF165 DNA was injected into the
myocardium of five patients who had failed standard therapy.
SPECT imaging demonstrated reduced ischemia [17]. Aden-
oviral delivery of VEGF121 to the myocardium of 21 patients
by direct injection, either as an adjunct to coronary bypass
grafting or as the sole therapy, led to improvement in the area
injected, as measured by angiography; angina was also
reduced [18]. Administration of recombinant VEGF121
improved function, as detected by SPECT [19]. Furthermore,
this study revealed a dose-dependent improvement in both
stress perfusion and rest perfusion; there was an infrequent
response in patients who received low dose VEGF and an
improvement in five out of six patients who received high
dose VEGF. In a different approach, VEGF cDNA was deliv-
ered via liposomes by catheter to coronary arteries following
angioplasty [20]. While this phase I safety trial did not show
an effect of VEGF-A on the degree of coronary ischemia, it
did prove that the treatment was well tolerated.
It is important to note that no phase II controlled studies using
defined and quantifiable endpoints have demonstrated effi-
cacy of therapeutic angiogenesis. This highlights the main
obstacles for assessing a therapeutic response to angiogene-
sis therapy, the reliability of the assessment methods and the
possible complications of the placebo effect. There is thus a
critical need for more controlled trials and for the development
of better defined and more quantifiable endpoints.Current Controlled Trials in Cardiovascular Medicine    December 2001 Vol 2 No 6 Ng and D’Amore
Modes of delivery
Delivery strategy is one of the most important variables when
using angiogenic factors to treat pathological conditions.
Expression of VEGF-A is tightly controlled during develop-
ment, and slight changes in VEGF-A protein levels are associ-
ated with developmental abnormalities and embryonic
lethality [21,22••]. Additionally, the unregulated expression of
VEGF-A in the myocardium has been reported to produce
deleterious cardiac effects in an animal model, causing
cardiac failure and death [23••]. Clearly, if VEGF-A is to be
used for therapeutic angiogenesis, tight control of its levels
must be achieved.
Protein therapy
At present, the administration of protein seems to be prefer-
able to gene therapy [12]. This is mainly because dosage
modulation in most clinical settings is far easier with purified
protein than with gene therapy, which is hampered by the
lack of a regulable expression vector. Although protein
therapy has many advantages, there are nevertheless techni-
cal problems associated with protein administration, including
optimization of purification and formulation of delivery for
single and/or multiple angiogenic factors.
Recent advances in drug delivery methods using bioerodible
polymer matrices will allow long-term sustained release of the
growth factors [24]. This will resolve one of the major prob-
lems associated with protein administration; namely, the
limited tissue half-life of the purified angiogenic factors in
patients. An important consideration, however, is that protein
therapy is limited to secreted factors. Delivery of intracellular
modulators for therapeutic angiogenesis, including transcrip-
tion factors that control angiogenesis such as hypoxia
inducible factor-1 alpha (HIF-1α), is only possible through
gene therapy.
Gene therapy
Viral vectors have been the most commonly used means of
gene delivery for both VEGF-A and FGF-2. Gene therapy pre-
sents an attractive alternative to purified proteins because it
offers the possibility of sustained production of one or more
factors following a single administration. Furthermore, tissue-
specific and highly localized production of the therapeutic
factor is possible, through the use of tissue-specific promoters.
However, a variety of issues have implications for the use of
viral vectors in gene therapy. Obvious potential concerns are
the immune and inflammatory responses to viral vectors.
Patients who received VEGF121 via an adenoviral vector had
increased levels of serum anti-adenoviral neutralizing antibod-
ies, but there was no report on an inflammatory response in
these patients [19]. The use of adenovirus-mediated gene
therapy in treating brain tumors has been reported to lead to
active brain inflammation as well as persistent (up to
3 months after treatment) transgene expression [25].
The lack of regulable gene expression is another potential
barrier. Some systems for inducible gene expressions have
proved to be effective and safe in animal models [26], but
have not yet been tested in humans. Recent advances in
stem cell research provide the possibility of combining gene
therapy with ex vivo gene transfer into stem cells for angio-
genesis therapy, as will be discussed later. If successful, this
approach may overcome most of the obstacles presented by
gene therapy.
Considerations for the future
Interpatient variability
It is not clear why some individuals develop a collateral cir-
culation sufficient to compensate for their ischemic vascu-
lar disease whereas others do not. Certainly, features such
as the extent of the disease and the time frame over which
the ischemia develops are contributing factors. However,
other previously unconsidered variables appear to play
important roles.
Collateral vessel development, as measured by blood pres-
sure, angiography, and vessel density, was significantly
reduced in old (4–5 years old) versus young (6–8 months
old) animals [27•], in a rabbit model of hind limb ischemia.
Endothelial cell dysfunction and reduced VEGF-A levels were
the reasons suggested for the reduced collateral response. A
subsequent study, demonstrating an age-dependent reduc-
tion in HIF-1α activity, provides one explanation for the lower
VEGF-A expression in response to hypoxia in aged animals
[28]. A reduced response to hypoxia might translate into a
weaker angiogenic response. This is supported by the fact
that the extent of hypoxic induction of VEGF-A in monocytes
correlates strongly with the presence of collateral vessels in
patients [29].
It is possible that genetic variability may also play a significant
role in an individual’s ability to generate collateral vessels in
response to ischemia, as well as their capacity to respond to
an exogenous angiogenic agent. Not surprisingly, a recent
report that assessed the angiogenic response in a murine
corneal pocket model to a fixed dosage of FGF-2 in various
strains of mice suggested that genetic backgrounds may
influence angiogenic response [30••]. A nearly 10-fold range
of response to the fixed dosage of FGF-2 was observed
among different inbred strains of mice, suggesting that
genetic variability may indeed play a significant role in deter-
mining the magnitude of angiogenic response to FGF-2.
Systemic effects
If VEGF-A delivery leads to significant circulating levels, as
has been observed following myocardial transfection with
VEGF-A cDNA [31], then it may possibly affect angiogenesis
elsewhere [32]. As plaque progression might be dependent
on angiogenesis [33], investigators were prompted to
examine the effect of VEGF-A administration on this process.
Mice that were double deficient in apolipoprotein E andAvailable online http://cvm.controlled-trials.com/content/2/6/278
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apolipoprotein β100 were treated with a single intraperitoneal
injection of VEGF165 recombinant human protein (2 µg/kg).
This led to significant increases in plaque area compared with
untreated controls [34••]. In contrast, there has been no evi-
dence of disease progression, to date, in 42 patients treated
with intra-arterial gene transfer of naked VEGF-A cDNA. This
has been delivered either to promote therapeutic angiogene-
sis (12 patients) or to accelerate re-endothelization (30
patients) [35]. Although these observations suggest that
human sensitivity to VEGF-A may be lower than in animal
models, it will be necessary to study a larger cohort of
patients, with appropriate controls, over a longer time period
to confirm this [36].
VEGF has also been shown to mediate the vessel growth that
characterizes tumor expansion as well as the neovasculariza-
tion that is associated with diabetic retinopathy. Although
VEGF is produced locally in both of these circumstances, it is
not known whether systemic administration of the factor
could exacerbate these conditions by further stimulating
vessel growth. Selection of the patient population that may
benefit from angiogenic therapy may thus have to involve
screening for coexisting conditions that could be activated or
worsened by exposure to proangiogenic agents.
VEGF-A, FGF-1, and FGF-2 have all demonstrated systemic
vascular effects. FGF-1 and FGF-2 have been shown to
reduce blood pressure in a dose-dependent manner in rats
[37]. Similarly, VEGF-A has been reported to cause hypoten-
sion and death in pigs following an intracoronary bolus
administration [38]. Subsequent studies have revealed that
VEGF-A administration causes greater vasodilatation of coro-
nary vessels than serotonin or nitroglycerin, and also causes
tachyphylaxis via a nitric oxide-dependent mechanism [39].
VEGF-A administration to the extremities of patients has also
been associated with hypotension and edema [40]. These
side effects can be partly explained by the fact that VEGF-A
is a potent vascular permeability factor.
VEGF-A isoforms in angiogenesis therapy
The five VEGF-A protein isoforms in humans (and at least
three major isoforms in the mouse) have different biochemical
and biological properties [41]. It is therefore important to
determine whether different VEGF-A isoforms give rise to dif-
ferent quality or quantity of vessels. Expression of the various
isoforms during development is modulated both spatially and
temporally [42], and observations from gene knockout
studies have proven that these isoforms do not have equiva-
lent biological functions during vessel development [42,43••].
Furthermore, there is considerable variability in the phenotype
of vessels in tumors expressing different isoforms [44]. For
example, vessels within tumors expressing predominantly the
VEGF189 isoform, which has a strong heparin-binding affinity
and thus is highly localized, are much less leaky than the
vessels in tumors expressing the more diffusible VEGF165
and VEGF121 isoforms [45]. It will be interesting and impor-
tant to determine whether these observations from experi-
mental systems can help predict the results of clinical trials,
which primarily employ the VEGF165 isoform. Finally, since
multiple VEGF-A isoforms are expressed during vascular
development [42], it will also be important to determine
whether the use of multiple isoforms in angiogenesis therapy
will be necessary to replicate in vivo conditions.
Achieving vessel stability
The induction of new vessels to supply ischemic tissues is
the primary goal of angiogenic therapy. Reaching this objec-
tive is, however, highly complex. Vessels formed in response
to artificial angiogenic stimuli are prone to regression unless
they are remodeled into mature, stable vessels [46]. Thus, as
the level of knowledge regarding the mechanisms of vessel
growth and stabilization increases, there is increasing
concern that the simple application of a bolus of angiogenic
factor may be insufficient for stable vessel formation, or may
even be dangerous.
Early studies involving the administration of VEGF-A showed
angiographic evidence of new vessel formation, but these
vessels did not persist and they regressed within 3 months
[40]. It was recently reported that continuous delivery of
VEGF-A into murine hearts by retroviral transfer led to the for-
mation of aberrant vessels and hemangioma-like structures
[23••]. One of the major problems encountered in the use of
VEGF-A is that vessels formed are unstable and leaky [47]. It
has been speculated that VEGF-A alone may not be sufficient
to form stable, mature vessels that are characterized by the
recruitment of the perivascular mural cells, such as pericytes
or smooth muscle cells [48]. This process of vessel matura-
tion is called arteriogenesis and is arguably the ideal way to
form stable vessels for therapeutic purposes [49].
Administration of multiple factors
Various growth factors such as angiopoietin (ang)-1, platelet-
derived growth factor, transforming growth factor-β as well as
VEGF-A are also involved in arteriogenesis, and it may there-
fore be necessary to use combinations of these factors to
obtain stable and mature vessels (Fig. 1). Indeed, when
VEGF-A and ang-1 are administered together in animal
models, the resulting vessels are much more stable and less
leaky than those that are induced by VEGF-A alone [50]. Sim-
ilarly, administration of submaximal doses of ang-1 and
VEGF-A in a rabbit ischemic hind limb model led to a
stronger effect on resting and maximal blood flow and capil-
lary formation than either of the agents alone [51].
Using a master switch gene
Another approach that addresses the involvement of multiple
factors in therapeutic angiogenesis is the use of a so-called
‘master switch gene’ of angiogenesis, such as HIF-1α [52].
This transcription factor can activate a collection of different
genes that are involved in angiogenesis, including those
encoding VEGF-A, VEGF receptor 1 (Flt-1), and ang-2[53,54]. It is hoped that using a ‘master switch gene’ will
result in more stable vessels, because the processes by
which they are formed would resemble more closely those of
normal vessel development.
Stem cells in therapeutic angiogenesis
The existence of circulating endothelial precursor (CEP) cells
in adults has been reported [55••,56]. It has also been
demonstrated that similar precursor cells may give rise to
both endothelial cells and perivascular mural cells [57].
Furthermore, in an in vitro model of angiogenesis, normal vas-
cular development has been shown to require the presence
of the CD45+/c-Kit+/CD34+ hematopoietic stem cells [58],
which are similar and may be related to adult CEP cells.
It has been reported that CEP cells are able to participate in
new vessel growth in a variety of animal models, including the
rabbit ischemic hind limb model [59]. In patients with inopera-
ble coronary disease, increased circulating VEGF-A resulting
from transfection of myocardium with VEGF165 cDNA led to
a significant mobilization of CEP cells [31]. Another recent
publication has shown that granulocyte-colony stimulating
factor mobilized CD34+ cells, including endothelial cell pre-
cursors with phenotypic and functional characteristics of
embryonic angioblasts [60••]. When injected into rats with
experimental myocardial infarction, these CD34+ cells con-
tributed to new vessel growth, which led to decreased car-
diomyocyte apoptosis, to reduced remodeling, and to
improved cardiac function.
Further studies of how CEP cells are released from bone
marrow and to what extent they participate in postnatal angio-
genesis will certainly provide valuable information regarding
the therapeutic potential of CEP cells. The possibility of using
CEP cells, both alone and in combination with different angio-
genic growth factors, represents a promising means of
obtaining stable vessels. Finally, since the use of CEP cells
would allow easy ex vivo gene transfer, combining growth
factor-induced therapeutic angiogenesis with gene therapy
delivered via CEP should also be a promising approach.
Conclusion
As research into therapeutic angiogenesis progresses, new
information regarding the control of vessel remodeling and
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Figure 1
Assembly of a stable vessel. Local increases in angiogenic factors such as fibroblast growth factor (FGF) and vascular endothelial growth factor
(VEGF) during new vessel formation destabilize a portion of an existing vessel (usually a venule). Destabilization is associated with increased
angiopoietin (ang)-2 expression and with pericyte activation, matrix remodeling, and induction of pericyte and endothelial cell (EC) migration and
proliferation. Newly formed vessels may be dependent on exogenous factors for their survival until they have been remodeled to mature structures.
Remodeling involves EC recruitment of pericyte/smooth muscle cell (SMC) precursors via endothelial-derived platelet-derived growth factor
(PDGF). Once the mural cell precursor makes contact with the vessel, transforming growth factor (TGF)-β is activated, which in turn suppresses
the proliferation and migration and induces the differentiation into SMC/pericytes. In addition to TGF-β, ang-1 produced by the SMC/pericytes is
also involved in the stabilization and maintenance of the stable mature vessel. aFGF, acidic fibroblast growth factor; bFGF, basic fibroblast growth
factor; CEP, circulating endothelial precursor.Available online http://cvm.controlled-trials.com/content/2/6/278
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stability will be incorporated into treatment strategies. Better
designed studies and clinical trials that consider the issues
discussed, coupled with well-defined and quantitative end-
points, will facilitate the development of novel and effective
therapeutic approaches for ischemic diseases.
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